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ess: gcromp@hotmail.cSummary Inability to use inhaler devices correctly is a major source of non-
compliance in patients with asthma. The problem of coordinating dose release with
inspiration seen with pressurised metered dose inhalers (pMDIs) is overcome by dry
powder inhalers (DPIs), since they use inspiratory flow energy to carry the drug dose
to the respiratory tract. The first DPIs were not popular because they were single
dose devices and inconvenient to use. The introduction of multiple dose DPIs
improved the image of the dry powder systems in the eyes of both the clinician and
the patient. The continued development of DPIs has led to inhaler devices which
include dose counters, are easy to use, are refillable and provide feedback to the
patient on a correct inhalation. Criteria that may improve patient compliance with
an inhaler include: correct use of the device by most patients; ease and convenience
of device use; dose release even at low inspiratory flow rates; feedback of drug
release which could instill confidence that the dose has been inhaled; cartridge
refills and overall confidence in the device. The Novolizers has all the desirable
features listed above and is expected to improve compliance if prescribed for the
large number of patients who cannot use the conventional pMDI or less efficient DPIs.
r 2004 Published by Elsevier Ltd.Introduction
There are numerous factors that influence patients’
compliance with drug therapy. In asthma, the
problem is greatly increased since inhaled treat-4 Published by Elsevier Ltd.
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om (G.K. Crompton).ment is the rational mainstay of therapy. Compared
to oral medication many patients find the inhaled
route is unnatural and this problem is compounded
by the fact that many inhalation devices are
difficult to use even by the most compliant
patients. The pressurised metered dose inhaler
(pMDI) was first introduced into clinical practice in
1956 in the USA. It very quickly became popular
with clinicians and remains the most commonly
prescribed inhalation device today, even though its
design has remained unchanged for many years and
many patients find it difficult to use.1,2 Inability to
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patient non-compliance with therapy. At least 50%
of adults and even more children cannot use pMDIs
efficiently mainly because of the difficulty of
coordinating dose release with inspiration.3–5 In
this large proportion of the asthmatic population
good compliance with treatment is therefore
impossible irrespective of the individual patient’s
desires.
This article will discuss the problems associated
with pMDIs and dry powder inhalers (DPIs) currently
on the market, as well as factors likely to improve
patient compliance and examine how the many
features of the Novolizers, a new multidose DPI
produced by VIATRIS Germany, could improve
patient compliance.Natural history of inhaler devices
In 1956, almost 50 years ago, the pMDI was
launched in the US and has remained essentially
unchanged since then. However, it soon became
apparent that many patients had difficulty using
this device correctly, most notably coordinating
device activation with inspiration proved proble-
matic. Coordination difficulties resulted in deposi-
tion of a large proportion of drug in the mouth and
oropharynx. Spacers were introduced in the 1970s
and 1980s to eliminate this problem, but the bulky
nature of spacers made them inconvenient to carry
and so were not conducive to compliance with
therapy. In an effort to preclude the need for
patients to coordinate device activation with
inhalation, the first successful breath-activated
pMDI was launched in 1989 in the UK. These
breath-activated inhalers were much easier for
patients to use correctly. However, in 1995 the
Montreal Protocol banned the use of chlorofluor-
ocarbon (CFC) propellant gases in pMDIs in a bid to
protect the ozone layer from further depletion.6
Ironically, pharmaceutical companies replaced CFCs
with hydrofluorocarbons (HFAs) which are 2000
times more potent green house gases than CFCs.
DPIs first appeared on the market in the late
1960s. The Spinhalers (Fisons) was introduced in
1969 to deliver sodium cromoglycate as pMDIs were
not suitable to deliver this drug in sufficient
quantities. The Rotahalers (GlaxoSmithKline) ap-
peared in 1977 closely followed by the Diskhalers
(GlaxoSmithKline) in 1980, the first of the foil
blister inhalers. The first multidose gravity feed
DPI, the Turbuhalers (Astra Zeneca), was intro-
duced in the UK in 1988. The Diskuss/Accuhalers
(GlaxoSmithKline) was launched in 1994 and is amodification of the Diskhalers system Finally in
2001, the Novolizers (VIATRIS, Germany) entered
the market.Disadvantages with pressurised metered
dose inhalers
The main disadvantage with pMDIs is that patients
cannot use them correctly.3–5,7–10 Patients fre-
quently fail to continuously inhale slowly after
activation of the inhaler and exhale fully before the
inhalation.11,12 In addition, patients often activate
the inhaler before inhalation or at the end of
inhalation and conclude inhaler activation while
breath-holding.3,12
Gayrard and Orehek4 assessed pMDI use in a
group of 115 asthmatics. Patients were divided into
two groups. The first group received instruction on
the correct use of their pMDI by a physician and the
need for correct inhaler use was strongly empha-
sised. The second group received no instruction and
used their inhaler according to manufacturers’
instructions. The inhalation technique was consid-
ered correct when (1) the puff release was
coordinated with a deep inspiration and (2) when
the inspiration was followed by a few seconds’
breath-holding. Seventy-two percent of patients
who received no instruction were unable to use
their pMDI correctly compared to 48% after
physician training. A German study carried out in
207 patients revealed that almost half of these
patients (47%) used their pMDI inadequately,
women more frequently than men.7 Most frequent
errors included an insufficient expiration before
inhalation and a lack of coordination between
inhaler activation and patient inhalation. A Spanish
study in 1640 volunteers (746 patients, 466 nurses,
428 physicians)8 showed that a staggering 91% of
patients were unable to use their pMDI correctly
compared with 85% of nurses and 72% of physicians.
Worryingly, general practitioners and paediatri-
cians had the worst inhaler technique compared
to chest physicians and allergists.8
A series of studies by Crompton and colleagues
investigating pMDI use during the period 1982–2000
produced similar results.3,5,9,10 Inhaler technique
was assessed after patients read the inhaler
package insert. Those patients who showed inade-
quate inhaler technique were instructed by trained
personnel and then retested. Results are sum-
marised in Table 1. In 1982, 80 patients (13%), out
of an original 1173 out-patients attending hospital
during a 3-month period, who had been able to use
a pMDI efficiently in the part were found to have
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Table 1 Percentage of patients who could use a
pressurised metered dose inhaler correctly after
reading the package insert and after receiving
physician instruction.
Year Pamphlet
instruction (%)
Physician
instruction (%)
19823 54 —
19879 47 62
198910 39 63
20005 21 52
Compliance with inhaled asthma therapy S37developed a poor technique.3 Problems encoun-
tered operating the pMDI included difficulty co-
ordinating aerosol release with inspiration (54%
patients), stopping inhalation upon release of the
aerosol (24% patients) and inspiring through the
nose whilst actuating the inhaler in the mouth (12%
patients).3 In subsequent studies the percentage of
patients who could correctly use a pMDI after
reading the instruction pamphlet or after receiving
instruction continued to fall (Table 1). By 2000,
only 21% of patients were able to correctly use a
pMDI after reading the package insert and only 52%
of patients correctly used a pMDI after receiving
instruction.5
Previous ability to correctly use a pMDI was not
indicative of correct use during subsequent test-
ing.1,3 For example in a study carried out in 1976,
50 patients out of a total of 321 patients (14%) who
had documented evidence of correct inhaler
technique proved to have totally inefficient co-
ordination of inspiration and inhaler activation.1 In
a study carried out in 1982,3 13% of patients already
being treated with drugs by inhalation had a poor
inhaler technique, even though most had received
instruction on how to use a pressurised aerosol and
were considered to be able to use one of these
devices correctly. Furthermore, 12% (this should be
of the 13% found to have an inefficient technique)
of patients already being treated with inhalers
actuated the aerosol on two or more occasions
during one inspiration.3
These observations suggest that the majority of
asthmatic patients probably derive incomplete
benefit from the use of pMDIs. Although training
apparently results in a more efficient use of the
canisters, training sessions must be repeated, and
the results checked at regular intervals by a
member of the medical staff. In patients who
repeatedly fail to achieve a correct inhalation
technique, the drug should be given using an
alternative inhalation device. The improper use ofpMDIs is not confined to patients. Both nurses and
physicians have also been shown to use pMDIs
incorrectly despite their increased awareness of
the importance of a correct inhalation technique in
the use of the pMDI. Substantial changes in
educational efforts are clearly required and should
be particularly addressed towards the general
practitioner and asthma nurse who in turn teach
patients how to use their inhaler device correctly.
Pressurised MDIs are clearly inefficient, user-
unfriendly devices which require good coordination
between inspiration and inhaler activation. Ap-
proximately 50% of adults are unable to use their
pMDI correctly even when taught. Indeed, intensive
training is required in the correct use of pMDIs and
frequent retesting is also recommended.13 More
than 10% of patients develop poor technique with
continued use if checks are not made, and children
have far more problems using the device than
adults. Compared with new DPIs, pMDIs deposit
approximately one-third of the drug into the lungs
and deposition rates depend upon inhaler techni-
que.3 Efficient use requires an optimal inspiratory
flow and a breath-hold of at least 6 s.14 Used with a
spacer device, bulkiness may reduce patient
compliance; without a spacer device a high
proportion of drug is deposited in the mouth and
orthopharynx.15 Finally, pMDIs contain no inhala-
tion control mechanisms, have no dose counter, and
contain environmentally unfriendly propellant
gases (e.g. HFAs). On the plus side pMDIs are cheap
and convenient. However, convenience is irrelevant
if patients cannot use the device correctly. The
consequence of not using a pMDI correctly is lack of
clinical effect.16 Continually changing inhaler de-
vices which deliver the same drug is not the
answer, as patients not only loose confidence in
the device but also in the drug and compliance
with therapy becomes poor. Therefore, poor
compliance with therapy can still occur even if
the patient is switched to an inhaler that they can
use. The lesson to be learned from this clinical
experience is do not prescribe an inhaler unless you
are absolutely certain that the patient can use it
properly.Disadvantages with dry powder inhalers
The DPI is breath-activated and minimal coordina-
tion is required between actuation and inspiration.
DPIs achieve higher pulmonary deposition than
pMDIs and they are environmentally friendly as
they do not contain propellant gases. There are
many DPIs currently on the market. These devices
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dose devices or multidose devices. Although DPIs,
as a class of delivery device, offer both the patient
and the physician many advantages over pMDIs,
individually they do have some limitations of
design, cost-effectiveness and/or user-friendliness.
Spinhalers (Fisons) and Rotahalers
(GlaxoSmithKline)
The Spinhalers and Rotahalers are single dose
devices. Doses are individually loaded into gelatine
capsules, each of which is loaded into the inhaler
immediately before use. When using these devices
there is no inhalation control system and the
patient receives no feedback that the dose has
been successfully released or that the patient has
inhaled correctly. Additionally, a high inspiratory
flow must be achieved to generate a fine particle
fraction (FPF) suitable for drug deposition in the
lungs. For each inhalation a new capsule needs to
be inserted into the device which is inconvenient
for the patient and does not allow for dose
counting. Also, the inhalation process may have to
be repeated until the capsule is empty which may
give rise to high dose variability.
Diskhalers
The Diskhalers (GlaxoSmithKline) was the proto-
type of the Diskuss, and is still used to some
degree in the UK, although it does have a
complicated usage. It is an example of a multiple
unit dose device as it contains a series of foil
blisters on a disk. These disks have to be frequently
changed and the device cleaned before refilling.
Turbuhalers
The Turbuhalers is the most frequently prescribed
DPI as it produces good deposition of drug in the
lungs provided that a sufficient inspiratory flow has
been achieved by the patients (i.e. 60 l/min). It is
an example of a multidose reservoir device.
However, many features of the Turbuhalers gen-
erate uncertainty for both the physician and the
patient. For example, the Turbuhalers exhibits
high dose variation,17 the particle size generated is
dependent on patients’ inspiratory flow rate,18 it
has lower drug deposition rates than the Novoli-
zers19 at optimal inspiratory flows and is not easy
to use by virtue of its high intrinsic resistance. In
fact, the resistance of the Turbuhalers is approxi-
mately twice that of the Novolizers. Using the
Turbuhalers, good deposition is only achieved whenthe patient achieves a sufficient inspiratory flow
(i.e.460 l/min). At lower inspiratory flow rates, as
may occur in young and elderly patients as well as
those with severe airflow obstruction, inhalation
through the Turbuhalers is likely to result in high
oral and low lung deposition. Indeed, patients may
be able to easily generate 60 l/min one day but on
another day, due to the variable nature of airflow
limitation seen in asthma, may be unable to reach
an inspiratory flow sufficient to operate the
Turbuhalers effectively. In addition, patients must
inhale sharply through the Turbuhalers at the
beginning of the inhalation manoeuvre to ensure
desagglomeration of drug particles and hence
effective pulmonary drug deposition.18 Finally,
there is no feedback to the patient that
sufficient medication has been successfully deliv-
ered. The device is not refillable, there is no
inhalation control mechanism, the dose counter is
limited and the amount of drug released from the
device might be reduced in conditions of high
humidity.20Pressurised MDIs vs DPIs
A study carried out by Crompton and colleagues5
assessed patients’ use of different inhaler devices,
ascertained whether patient device preference was
indicative of ease of use and whether current
inhaler use had any influence on either technique
or device preference. One hundred inhaler-naı¨ve
patients received instruction, in randomised order,
in the use of several different inhaler devices
(pMDI, Easi-Breaths, Authohalers, Diskuss, Clic-
khalers, Turbuhalers). After instruction patients
were graded (using predetermined criteria) in their
inhaler technique. Technique was best using the
breath-actuated inhalers; the Easi-Breathes and
Autohalers, with 91% of patients observed to have
good technique following instruction (61% prior to
instruction). The Turbuhalers did not fare as well,
with only 47% of patients being able to correctly
use it after reading the package insert which rose
to 90% following expert instruction. The pMDI fared
worst of all, in last position with only 21% of
patients showing good technique, despite being the
most commonly prescribed device. Following in-
struction by an expert, only 52% of patients showed
good inhaler technique with the pMDI. The majority
of patients (55%) currently used the pMDI but the
pMDI did not score highly for preference or achieve
better grades than the other devices. This has
important repercussions for drug delivery and
hence disease control. There is no advantage to
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that the patient cannot use correctly. Prescribing a
patient’s preferred device may increase cost but
can improve efficiency and therefore be more cost-
effective in the long-term. Using an inexpensive
device (pMDI) when technique is good, or the
patient’s preferred inhaler device when pMDI
technique is poor is one way to optimise delivery
and may even reduce cost.5Figure 1 Patient satisfaction with the control features of
the Novolizers. Reprinted with permission from Mo¨ller et
al.21The Novolizers may improve patient
compliance
A large post-marketing surveillance study carried
out in 3057 patients suffering from allergic, non-
allergic or mixed bronchial asthma evaluated the
efficacy, tolerability and acceptance of the Novo-
lizers (containing budesonide 200 mg).21 Most of
the patients (54%) used a pMDI prior to the study,
21% of patients used a DPI but all were on inhaled
corticosteroids prior to switching to the Novoli-
zers. Patients treated with budesonide delivered
via the Novolizers for 4 weeks showed a decrease
in the severity of their symptoms. The median total
symptom score fell from 8 before therapy to 2 after
therapy. PEF also increased from 5 l/s prior to
therapy to 6.3 l/s at the end of therapy, with a
median individual increase of 1 l/s. FEV1 showed a
similar improvement increasing from 2.25 l before
therapy to 2.7 l after therapy (a median individual
increase of 310ml).21 This reduction in symptoms
and improvement in lung function following treat-
ment with the budesonide Novolizers for 4 weeks
may have been due to improved compliance with
therapy.
Patients’ satisfaction in dealing with the control
mechanisms (i.e. optical, acoustic, taste, dose
counter, overdose prevention) of the Novolizers
was also assessed.21 Patients who already had used
another inhalation system assessed the control
mechanisms of the Novolizers in comparison with
their previous inhaler. Results of the study showed
that the majority of patients were satisfied with
the control mechanisms of the Novolizers (Fig. 1).
Ninety-seven percent of patients were satisfied
with the optical control mechanism, 94% with the
acoustic mechanism, 78% with the taste feedback,
92% with the dose counter and 81% with the
overdose prevention system. This is an important
result as patients who are satisfied with their
inhalation device are more likely to be compliant
with their treatment regimen. It follows that
improved compliance should lead to improved
asthma control.Patients’ compliance and any improvement in
compliance by the control mechanisms of the
Novolizers were evaluated by physicians and
patients.21 Compliance was assessed by physicians
to be good in 84% of the patients, satisfactory in
14% of patients and unsatisfactory in the remaining
2% of patients. An improvement in compliance by
the control mechanisms of the Novolizers was
observed in 80% of the patients. Eighty-eight
percent of patients felt that the optical feedback
system improved their compliance, 81% thought the
click noise improved their compliance but only 46%
of patients thought the taste feedback improved
their compliance. The vast majority of patients
(91%) assessed the control mechanisms of the
Novolizers to be better or much better than those
of a previously used inhaler (e.g. Diskuss or
Turbuhalers). These results suggest that the con-
trol mechanisms of the Novolizers are well-
accepted by patients and considered by physicians
as an important contributor to improved patient
compliance.Conclusion
Factors important in patient compliance with
therapy include correct use of inhaler device; ease
and convenience of use; control of dose release;
confidence that drug has been released and
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Figure 2 Novel features of the Novolizers which may
improve patient compliance with therapy.
G.K. CromptonS40inhaled; cartridge refills; and accuracy and con-
sistency of dose release. The Novolizers fulfils all
these compliance criteria (Fig. 2). The Novolizers
is a convenient device and easy to use correctly.
The portable nature of the device and multidose
design make the Novolizers convenient for pa-
tients to use. Ease of use as well as confidence that
drug has been released is assured by the multiple
feedback system which guides patients through the
inhalation procedure in a step by step fashion. In
addition, dose release is indicated by a trigger flow
valve which helps to ensure that sufficient drug is
released for optimal pulmonary deposition. The
Novolizers with its multiple feedback mechanisms
and trigger flow valve system is a device which
gives patients confidence that drug has been
inhaled and deposited in sufficient quantities into
their lungs. The Novolizers is a refillable device
which makes it an environmentally friendly and
cost-effective option. Cartridge change is simply a
matter of opening the inhaler, removing the old
cartridge and replacing it with a new one. Drug
release from the Novolizers has been shown to be
consistent under ‘real life’ conditions; the emitted
mass and FPF of drug released from the device is
relatively independent of patients’ inspiratory flow
profile and unaffected by conditions of high
temperature and humidity.22 Finally, patients who
have used the Novolizers express a preference for
it and are satisfied with the control features of the
device. In conclusion, the Novolizers has many
features which should improve patient compliance,
and improved patient compliance should lead to
better control of asthma.References
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